AMT-562

Multitude Therapeutics (Australia) Pty Ltd · Phase 1 active Small molecule

At a glance

Generic name	AMT-562
Sponsor	Multitude Therapeutics (Australia) Pty Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AMT-562 in Patients With Selected Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AMT-562 CI brief — competitive landscape report
AMT-562 updates RSS · CI watch RSS
Multitude Therapeutics (Australia) Pty Ltd portfolio CI